Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but Not with Vascular Dementia

다국어 초록 (Multilingual Abstract)

Purpose: We aimed to investigate the association between androgen deprivation therapy (ADT) and the risk of dementia according to subtypes of dementia in men with prostate cancer.
Materials and Methods: We performed a nationwide population-based cohort study using the nationwide claims database in Korea. A total of 195,308 men with newly diagnosed prostate cancer were identified between January 2008 and December 2017, and 132,700 men were selected for analysis after applying inclusion and exclusion criteria. The patients were divided into ADT and non-ADT groups. To adjust for imbalances in relevant comorbidities between the groups, exact matching was performed. Study events included newly developed Alzheimer’s disease, vascular dementia, and overall dementia. Cox proportional hazard regression models were used.
Results: After exact matching, 44,854 men with prostate cancer were selected for the main analysis. In age-adjusted Cox regression analysis, the ADT group was significantly associated with increased risks for overall dementia (hazard ratio [HR], 1.070; 95% confidence interval [CI], 1.009–1.134; p=0.0232) and Alzheimer’s disease (HR, 1.086; 95% CI, 1.018–1.160; p=0.0127), compared to the non-ADT group. No difference in vascular dementia risk was observed between the two groups (HR, 0.990; 95% CI, 0.870–1.126; p=0.8792).
Conclusions: The risk of overall dementia increased in men who received ADT. According to dementia subtypes, ADT was associated with an increased risk of Alzheimer’s disease, but not with vascular dementia.

참고문헌 (Reference)

1 Mi X, "Use of the landmark method to address immortal person-time bias in comparative effectiveness research : a simulation study" 35 : 4824-4836, 2016

2 Boyle HJ, "Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients" 116 : 116-136, 2019

3 Sari Motlagh R, "The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy : a systematic review and metaanalysis" 205 : 60-67, 2021

4 Holland J, "Testosterone levels and cognition in elderly men : a review" 69 : 322-337, 2011

5 Levin KA, "Study design IV. Cohort studies" 7 : 51-52, 2006

6 Cho IS, "Statistical methods for elimination of guarantee-time bias in cohort studies : a simulation study" 17 : 126-, 2017

7 Smith MR, "Side effects of androgen deprivation therapy" UpToDate

8 Baik SH, "Risk of Alzheimer's disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer" 35 : 3401-3409, 2017

9 Pike CJ, "Protective actions of sex steroid hormones in Alzheimer's disease" 30 : 239-258, 2009

10 Almeida OP, "One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men" 29 : 1071-1081, 2004

11 Cochran WG, "Matching in analytical studies" 43 (43): 684-691, 1953

12 Carcaillon L, "Low testosterone and the risk of dementia in elderly men : impact of age and education" 10 (10): S306-14, 2014

13 Hsu B, "Longitudinal relationships between reproductive hormones and cognitive decline in older men : the Concord Health and Ageing in Men Project" 100 : 2223-2230, 2015

14 신말순 ; 김태운 ; 박상서 ; 고일규 ; 김창주 ; 김미아 ; 노수연 ; 김광택 ; 김계환, "Long-term Surgical and Chemical Castration Deteriorates Memory Function Through Downregulation of PKA/CREB/ BDNF and c-Raf/MEK/ERK Pathways in Hippocampus" 대한배뇨장애요실금학회 23 (23): 116-124, 2019

15 Jepsen P, "Interpretation of observational studies" 90 : 956-960, 2004

16 Alibhai SM, "Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer" 28 : 5030-5037, 2010

17 Sosa-Ortiz AL, "Epidemiology of dementias and Alzheimer's disease" 43 : 600-608, 2012

18 Chao HH, "Effects of androgen deprivation on cerebral morphometry in prostate cancer patients--an exploratory study" 8 : e72032-, 2013

19 Chao HH, "Effects of androgen deprivation on brain function in prostate cancer patients-a prospective observational cohort analysis" 12 : 371-, 2012

20 Kim DK, "Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study" 147 : 1217-1226, 2021

21 Kim JH, "Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia : metaanalysis and meta-regression" 8 : 73087-73097, 2017

22 Keating NL, "Diabetes and cardiovascular disease during androgen deprivation therapy : observational study of veterans with prostate cancer" 104 : 1518-1523, 2012

23 Livingston G, "Dementia prevention, intervention, and care" 390 : 2673-2734, 2017

24 Meng MV, "Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer" 60 (60): 7-11, 2002

25 Deka R, "Association of androgen deprivation therapy with dementia in men with prostate cancer who receive definitive radiation therapy" 4 : 1616-1617, 2018

26 Jayadevappa R, "Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer" 2 : e196562-, 2019

27 Robinson D, "Androgen deprivation therapy for prostate cancer and risk of dementia" 124 : 87-92, 2019

28 Khosrow-Khavar F, "Androgen deprivation therapy and the risk of dementia in patients with prostate cancer" 35 : 201-207, 2017

29 Green HJ, "Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate : a randomized controlled trial" 90 : 427-432, 2002

30 Kim L, "A guide for the utilization of Health Insurance Review and Assessment Service national patient samples" 36 : e2014008-, 2014